Dr Reddy’s has announced a denosumab licensing deal with Alvotech covering the US and Europe, for which the Indian company has broken down the financial details. More broadly, the alliance will also allow Dr Reddy’s to build up its commercial infrastructure for biosimilars in both key markets.
Dr Reddy’s has struck a fresh biosimilar commercialization deal, announcing an alliance with Alvotech on denosumab that will give the Indian firm “exclusive commercialization rights in the US as well as semi-exclusive rights in Europe and the UK” to Alvotech’s AVT03 candidate.
Alvotech and Dr Reddy’s said the collaboration on the Prolia/Xgeva biosimilar “combines Dr Reddy’s global commercial presence with Alvotech’s proven...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
